However, in the Cardiovascular Inflammation Reduction Trial (CIRT), low-dose methotrexate did not reduced the levels of inflammatory biomarkers IL-1β, IL-6 or CRP in patients with previous history of myocardial infarction or coronary disease and did not reduced the frequency of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death or unstable angina [26]. Here, IL6 is linked to myocardial infarction.